Cytokine profiles in localized scleroderma and relationship to clinical features

Cytokine

Volumn 55, Issue 2, 2011, Pages 157-164

  Kurzinski, Katherine ^a   Torok, Kathryn S ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Cytokines; Localized scleroderma; T lymphocytes

Indexed keywords

AUTOANTIBODY; CYTOKINE; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8; INTERLEUKIN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL PROLIFERATION; CLINICAL FEATURE; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; LOCALIZED SCLERODERMA; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; TH2 CELL;

AUTOANTIBODIES; CYTOKINES; HUMANS; RECEPTORS, INTERLEUKIN; SCLERODERMA, LOCALIZED; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 79959540034     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2011.04.001     Document Type: Review

References (68)

1. Peterson L.S., Nelson A.M., Su W.P., Mason T., O'Fallon W.M., Gabriel S.E. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. J Rheumatol 1997, 24(1):73-80.
2. Peterson L.S., Nelson A.M., Su W.P. Classification of morphea (localized scleroderma). Mayo Clin Proc 1995, 70(11):1068-1076.
3. Lever W.F., Elder D.E., Elenitsas R., Jaworsky C., Johnson B.L. Lever's histopathology of the skin 1997, Lippincott-Raven, Philadelphia. 8th ed.
4. McKee P.H. Pathology of the skin: with clinical correlations 1996, Mosby-Wolfe, London. 2nd ed.
5. Zulian F. New developments in localized scleroderma. Curr Opin Rheumatol 2008, 20(5):601-607.
6. Roumm A.D., Whiteside T.L., Medsger T.A., Rodnan G.P. Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. Arthritis Rheum 1984, 27(6):645-653.
7. Torres J.E., Sanchez J.L. Histopathologic differentiation between localized and systemic scleroderma. Am J Dermatopathol 1998, 20(3):242-245.
8. Needleman B.W., Wigley F.M., Stair R.W. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 1992, 35(1):67-72.
9. Hasegawa M., Fujimoto M., Kikuchi K., Takehara K. Elevated serum levels of interleukin-4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 1997, 24(2):328-332.
10. Salmon-Ehr V., Serpier H., Nawrocki B., Gillery P., Clavel C., Kalis B., et al. Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in fibrosis. Arch Dermatol 1996, 132(7):802-806.
11. Kahaleh M.B., LeRoy E.C. Interleukin-2 in scleroderma: correlation of serum level with extent of skin involvement and disease duration. Ann Intern Med 1989, 110(6):446-450.
12. Lis A., Brzezinska-Wcislo L. Interleukin-2 and interleukin-6 in serum as markers of disease progression in systemic sclerosis. Pol Merkuriusz Lek 2001, 11(63):206-209.
13. Alecu M., Geleriu L., Coman G., Galatescu L. The interleukin-1, interleukin-2, interleukin-6 and tumour necrosis factor alpha serological levels in localised and systemic sclerosis. Rom J Intern Med 1998, 36(3-4):251-259.
14. Ihn H., Sato S., Fujimoto M., Kikuchi K., Takehara K. Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res 1995, 287(2):193-197.
15. Thornton S.C., Por S.B., Walsh B.J., Penny R., Breit S.N. Interaction of immune and connective tissue cells: I. The effect of lymphokines and monokines on fibroblast growth. J Leukoc Biol 1990, 47(4):312-320.
16. Cho M.M., Jimenez S.A., Johnson B.A., Harlow L.A., Burrows J.C., Koch A.E. In vitro cytokine modulation of intercellular adhesion molecule-1 expression on systemic sclerosis dermal fibroblasts. Pathobiology 1994, 62(2):73-81.
17. Hasegawa M., Fujimoto M., Kikuchi K., Takehara K. Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: association with pulmonary fibrosis. J Rheumatol 1997, 24(4):663-665.
18. Jablons D.M., Mule J.J., McIntosh J.K., Sehgal P.B., May L.T., Huang C.M., et al. IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans. J Immunol 1989, 142(5):1542-1547.
19. Hasegawa M., Sato S., Nagaoka T., Fujimoto M., Takehara K. Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma. Dermatology 2003, 207(2):141-147.
20. Doucet C., Brouty-Boye D., Pottin-Clemenceau C., Jasmin C., Canonica G.W., Azzarone B. IL-4 and IL-13 specifically increase adhesion molecule and inflammatory cytokine expression in human lung fibroblasts. Int Immunol 1998, 10(10):1421-1433.
21. Kodera T., McGaha T.L., Phelps R., Paul W.E., Bona C.A. Disrupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from embryonic death and diminishes TGF-beta production by fibroblasts. Proc Natl Acad Sci USA 2002, 99(6):3800-3805.
22. Fertin C., Nicolas J.F., Gillery P., Kalis B., Banchereau J., Maquart F.X. Interleukin-4 stimulates collagen synthesis by normal and scleroderma fibroblasts in dermal equivalents. Cell Mol Biol 1991, 37(8):823-829.
23. Peyron E. Interleukin-4; structure, function and clinical aspects. Eur J Dermatol 1994, 4:181-188.
24. Wegrowski Y., Paltot V., Gillery P., Kalis B., Randoux A., Maquart F.X. Stimulation of sulphated glycosaminoglycan and decorin production in adult dermal fibroblasts by recombinant human interleukin-4. Biochem J 1995, 307(Pt 3):673-678.
25. Shingu M., Miyauchi S., Nagai Y., Yasutake C., Horie K. The role of IL-4 and IL-6 in IL-1-dependent cartilage matrix degradation. Br J Rheumatol 1995, 34(2):101-106.
26. Sato S., Fujimoto M., Ihn H., Kikuchi K., Takehara K. Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma. J Am Acad Dermatol 1994, 31(4):567-571.
27. Oriente A., Fedarko N.S., Pacocha S.E., Huang S.K., Lichtenstein L.M., Essayan D.M. Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 2000, 292(3):988-994.
28. Garrett-Sinha L.A., John S., Gaffen S.L. IL-17 and the Th17 lineage in systemic lupus erythematosus. Curr Opin Rheumatol 2008, 20(5):519-525.
29. Stockinger B., Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol 2007, 19(3):281-286.
30. Fitch E., Harper E., Skorcheva I., Kurtz S.E., Blauvelt A. Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 2007, 9(6):461-467.
31. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6(11):1133-1141.
32. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6(11):1123-1132.
33. Torok K., Arkachaisri T., Medsger T.A., Feghali-Bostwick C.A. Th1 and Th17 cytokine signatures in early pediatric localized scleroderma. Arthritis Rheum 2010, 62(10):S839.
34. Yao Z., Painter S.L., Fanslow W.C., Ulrich D., Macduff B.M., Spriggs M.K., et al. Human IL-17: a novel cytokine derived from T cells. J Immunol 1995, 155(12):5483-5486.
35. Fossiez F., Djossou O., Chomarat P., Flores-Romo L., Ait-Yahia S., Maat C., et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996, 183(6):2593-2603.
36. Kurasawa K., Hirose K., Sano H., Endo H., Shinkai H., Nawata Y., et al. Increased interleukin-17 production in patients with systemic sclerosis. Arthritis Rheum 2000, 43(11):2455-2463.
37. Naka T., Nishimoto N., Kishimoto T. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002, 4(Suppl. 3):S233-S242.
38. Romero L.I., Pincus S.H. In situ localization of interleukin-6 in normal skin and atrophic cutaneous disease. Int Arch Allergy Immunol 1992, 99(1):44-49.
39. Kadono T., Kikuchi K., Ihn H., Takehara K., Tamaki K. Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol 1998, 25(2):296-301.
40. Gourh P., Arnett F.C., Assassi S., Tan F.K., Huang M., Diekman L., et al. Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations. Arthritis Res Ther 2009, 11(5):R147.
41. Varga J., Rosenbloom J., Jimenez S.A. Transforming growth factor beta (TGF beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J 1987, 247(3):597-604.
42. Edwards D.R., Murphy G., Reynolds J.J., Whitham S.E., Docherty A.J., Angel P., et al. Transforming growth factor beta modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 1987, 6(7):1899-1904.
43. Higley H., Persichitte K., Chu S., Waegell W., Vancheeswaran R., Black C. Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum 1994, 37(2):278-288.
44. Radstake T.R., van Bon L., Broen J., Hussiani A., Hesselstrand R., Wuttge D.M., et al. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes. PLoS One 2009, 4(6):e5903.
45. Verrecchia F., Laboureau J., Verola O., Roos N., Porcher R., Bruneval P., et al. Skin involvement in scleroderma - where histological and clinical scores meet. Rheumatology (Oxford) 2007, 46(5):833-841.
46. Querfeld C., Eckes B., Huerkamp C., Krieg T., Sollberg S. Expression of TGF-beta 1, -beta 2 and -beta 3 in localized and systemic scleroderma. J Dermatol Sci 1999, 21(1):13-22.
47. Uziel Y., Feldman B.M., Krafchik B.R., Laxer R.M., Yeung R.S. Increased serum levels of TGFbeta1 in children with localized scleroderma. Pediatr Rheumatol Online J 2007, 5:22.
48. Matsushima K., Oppenheim J.J. Interleukin 8 and MCAF: novel inflammatory cytokines inducible by IL 1 and TNF. Cytokine 1989, 1(1):2-13.
49. Larsen C.G., Anderson A.O., Oppenheim J.J., Matsushima K. Production of interleukin-8 by human dermal fibroblasts and keratinocytes in response to interleukin-1 or tumour necrosis factor. Immunology 1989, 68(1):31-36.
50. Reitamo S., Remitz A., Varga J., Ceska M., Effenberger F., Jimenez S., et al. Demonstration of interleukin 8 and autoantibodies to interleukin 8 in the serum of patients with systemic sclerosis and related disorders. Arch Dermatol 1993, 129(2):189-193.
51. Ihn H., Sato S., Fujimoto M., Kikuchi K., Takehara K. Demonstration of interleukin 8 in serum samples of patients with localized scleroderma. Arch Dermatol 1994, 130(10):1327-1328.
52. Zerler B. The soluble interleukin-2 receptor as a marker for human neoplasia and immune status. Cancer Cells 1991, 3(12):471-479.
53. Sondergaard K., Stengaard-Pedersen K., Zachariae H., Heickendorff L., Deleuran M., Deleuran B. Soluble intercellular adhesion molecule-1 (sICAM-1) and soluble interleukin-2 receptors (sIL-2R) in scleroderma skin. Br J Rheumatol 1998, 37(3):304-310.
54. Degiannis D., Seibold J.R., Czarnecki M., Raskova J., Raska K. Soluble and cellular markers of immune activation in patients with systemic sclerosis. Clin Immunol Immunopathol 1990, 56(2):259-270.
55. Lis A.D., Brzezinska-Wcislo L.A. Soluble receptors of cytokines in sera of patients with systemic sclerosis-clinical correlation. Wiad Lek 2003, 56(11-12):532-536.
56. Steen V.D., Engel E.E., Charley M.R., Medsger T.A. Soluble serum interleukin 2 receptors in patients with systemic sclerosis. J Rheumatol 1996, 23(4):646-649.
57. Ihn H., Sato S., Fujimoto M., Kikuchi K., Takehara K. Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma. Br J Dermatol 1996, 134(5):843-847.
58. Uziel Y., Krafchik B.R., Feldman B., Silverman E.D., Rubin L.A., Laxer R.M. Serum levels of soluble interleukin-2 receptor. A marker of disease activity in localized scleroderma. Arthritis Rheum 1994, 37(6):898-901.
59. Honda M., Yamamoto S., Cheng M., Yasukawa K., Suzuki H., Saito T., et al. Human soluble IL-6 receptor: its detection and enhanced release by HIV infection. J Immunol 1992, 148(7):2175-2180.
60. Narazaki M., Yasukawa K., Saito T., Ohsugi Y., Fukui H., Koishihara Y., et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood 1993, 82(4):1120-1126.
61. Yokoyama A., Kohno N., Hirasawa Y., Kondo K., Abe M., Inoue Y., et al. Evaluation of soluble IL-6 receptor concentration in serum and epithelial lining fluid from patients with interstitial lung diseases. Clin Exp Immunol 1995, 100(2):325-329.
62. Uson J., Balsa A., Pascual-Salcedo D., Cabezas J.A., Gonzalez-Tarrio J.M., Martin-Mola E., et al. Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies. J Rheumatol 1997, 24(11):2069-2075.
63. Mihara M., Moriya Y., Ohsugi Y. IL-6-soluble IL-6 receptor complex inhibits the proliferation of dermal fibroblasts. Int J Immunopharmacol 1996, 18(1):89-94.
64. Hasegawa M., Sato S., Fujimoto M., Ihn H., Kikuchi K., Takehara K. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis. J Rheumatol 1998, 25(2):308-313.
65. Nagaoka T., Sato S., Hasegawa M., Ihn H., Takehara K. Serum levels of soluble interleukin 6 receptor and soluble gp130 are elevated in patients with localized scleroderma. J Rheumatol 2000, 27(8):1917-1921.
66. Takehara K., Sato S. Localized scleroderma is an autoimmune disorder. Rheumatology (Oxford) 2005, 44(3):274-279.
67. Zulian F., Vallongo C., Woo P., Russo R., Ruperto N., Harper J., et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum 2005, 52(9):2873-2881.
68. Arkachaisri T., Fertig N., Pino S., Medsger T.A. Serum autoantibodies and their clinical associations in patients with childhood- and adult-onset linear scleroderma. A single-center study. J Rheumatol 2008, 35(12):2439-2444.